Fusion Pharmaceuticals

Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. The company was founded by John Vaillant in 2014 and is headquartered in Hamilton, Canada.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company. It is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production center. Fusion’s deep radiochemistry expertise presents a technology platform that can be replicated to turn internalizing antibodies that have previously demonstrated limited clinical efficacy into highly effective cytotoxic drugs. Fusion’s ability to link effective isotopes to the targeting antibody allows for the creation of optimized agents for both diagnostic imaging and radioimmunotherapy (Precision Medicine). Following positive tumor identification with the imaging agent, treatment with the antibody linked to a therapeutic isotope delivers a cytotoxic payload into the cancer cell. Fusion’s lead product candidate, FPX-01, is a precision RIT that is a product of this innovative approach. FPX-01 has been designed to internalize targeted cancer cells and deliver a lethal and highly localized radioactive payload. The precise targeting of this radiolabeled antibody causes selective and extremely effective cytotoxicity of tumor cells at relatively low doses of radioactivity.

HAMILTON, ON and BOSTON , March 5, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that interim efficacy and safety data from the Phase 2 TATCIST clinical trial evaluating FPI-2265 in patients with metastatic castration-resistant prostate cancer (mCRPC) has been selected for a clinical trial poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California. Presentation at AACR Annual Meeting 2024: Title: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) Session: Phase II Clinical Trials 1 Session Date and Time: Tuesday April 9, 2024, 9:00 a.m – 12:30 p.m.

Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting

Fusion Pharmaceuticals is an oncology company focused on precision medicine and radiopharmaceuticals. The company's clinical candidates show promise in targeting and treating cancers with unmet needs. Fusion has a strong financial position, with enough cash to fund operations until Q2 2025, and strategic partnerships to support its clinical pipeline.

Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook

Investor focus is likely to be on updates regarding Fusion Pharmaceuticals' (FUSN) pipeline candidates on the fourth-quarter conference call.

Fusion (FUSN) to Report Q4 Earnings: Here's What to Expect

HAMILTON, ON and BOSTON , Feb. 26, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming investor conferences. TD Cowen 44th Annual Health Care Conference - The Company will participate in the "Prostate Cancer Corporate Panel Discussion" taking place on March 4, 2024, at 10:30 a.m.

Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences

Chefs' Warehouse

CoreCivic

Goodyear Tire & Rubber

Halliburton

Pan American Silver

Vale S.A.

Buying call options is a lot like (American) football. Sometimes, you run the ball up the middle.

7 Low-Cost Call Options With High-Profit Potential

FPI-2265 positioned to be the first approved PSMA targeted alpha therapy HAMILTON, ON and BOSTON, Feb. 16, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into an exclusive worldwide license agreement with Heidelberg University and Euratom represented by the European Commission, Joint Research Centre (together, the "Licensors"). The license agreement grants Fusion exclusive worldwide rights to utilize, develop, manufacture and commercialize compounds covered by the patent, which includes 225Ac-PSMA I&T ("FPI-2265") for the treatment of prostate specific membrane antigen (PSMA)-expressing cancers.

Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy

HAMILTON, ON and BOSTON , Feb. 7, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present virtually at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024, at 10:00 a.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Fusion Pharmaceuticals Inc. (FUSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Fusion Pharmaceuticals Inc. (FUSN) Could Rally 35.09%: Here's is How to Trade

Fusion Pharmaceuticals Inc. (FUSN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Fusion Pharmaceuticals Inc. (FUSN) a New Strong Buy Stock

Rolls-Royce Holdings PLC

Let's take a look at the screen and a few of the over 50 highly-ranked cheap stocks to consider buying in January.

Finding the Best Cheap Stocks Under $10 to Buy in 2024

Does Fusion Pharmaceuticals Inc. (FUSN) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Fusion Pharmaceuticals Inc. (FUSN) a Strong Momentum Stock: Buy Now?

Here, we discuss some reasons why investing in Fusion Pharmaceuticals (FUSN) stock now may turn out to be a prudent move.

Is it a Good Idea to Buy Fusion Pharmaceuticals (FUSN) Stock Now?

Fusion Pharmaceuticals (FUSN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Fusion Pharmaceuticals (FUSN) Stock Stands Out in a Strong Industry

The average of price targets set by Wall Street analysts indicates a potential upside of 47.8% in Fusion Pharmaceuticals Inc. (FUSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Fusion Pharmaceuticals Inc. (FUSN) Have the Potential to Rally 47.76% as Wall Street Analysts Expect?

Aligned with the FDA on submitted protocol for 225Ac-PSMA (FPI-2265) Phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mCRPC) Achieved target enrollment in ongoing TATCIST trial evaluating FPI-2265; Interim Phase 2 data expected to be presented in April 2024 FPI-1434 shows promising safety profile and early evidence of antitumor activity at 25 kBq/kg dose level Fusion's state-of-the-art manufacturing facility now fully operational with first clinical dose produced HAMILTON, ON and BOSTON , Jan. 4, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced significant progress with its FPI-2265 development program, an update on FPI-1434 Phase 1 Cohort 2 data and the production of the first clinical doses at the Company's proprietary manufacturing facility.     "We begin 2024 with strong momentum, given a potential registration-enabling path for FPI-2265, encouraging results in our FPI-1434 program, including first signs of antitumor activity, and a fully operational TAT manufacturing facility that has already begun to produce clinical doses for our actinium-based PSMA lead program," said Chief Executive Officer John Valliant, Ph.D.

Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates

Fusion Pharmaceuticals (FUSN) surges to a new record level 52-week high after analysts at Raymond James upgraded its rating following the buyout announcements for two comparable companies.

Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday

Bristol-Myers

Eli Lilly

Point Biopharma Global

RayzeBio Inc

Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday.

Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target

Journey Medical Corp

Lyra Therapeutics

Novo Nordisk

Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.

4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow

The average of price targets set by Wall Street analysts indicates a potential upside of 149.5% in Fusion Pharmaceuticals Inc. (FUSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 149.52% Upside in Fusion Pharmaceuticals Inc. (FUSN): Here's What You Should Know

Here's Why Fusion Pharmaceuticals Inc. (FUSN) is a Great Momentum Stock to Buy

The mean of analysts' price targets for Fusion Pharmaceuticals Inc. (FUSN) points to a 162% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Fusion Pharmaceuticals Inc. (FUSN)? Wall Street Analysts Think 162%

Align Technology

Allstate

Chewy

Dynatrace Inc

DoubleVerify Holdings

Fiserv

Five Below

Hologic

Novanta

Since market valuations are always changing, along with outlooks for corporate revenue and earnings, any list of favored stocks is only a snapshot. Repeating the same analysis in the near term might lead to an entirely different list of compelling names.

10 ‘better values' in the stock market, selected for the next two years

BWX Technologies

OTTAWA, Ontario--(BUSINESS WIRE)--BWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator Technology.

BWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator Technology

Collaboration enables Fusion to produce high purity actinium-225 at Company's GMP manufacturing facility Agreement furthers BWXT Medical's position as a global leader in medical isotope supply HAMILTON, ON and BOSTON , Nov. 16, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT), today announced that the companies have entered into a new agreement for the supply of generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials.

Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical Collaboration

HAMILTON, ON and BOSTON , Nov. 8, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming investor conferences. Jefferies London Healthcare Conference – The Company fireside chat presentation will take place on Thursday, November 16, 2023 at 9:00 a.m.

Fusion Pharmaceuticals to Present at Upcoming Investor Conferences

News for Fusion Pharmaceuticals Stock (FUSN)